Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …

A higher incidence of colorectal cancer (CRC) is found in males compared to females.
Young women (18–44 years) with CRC have a better survival outcome compared to men of …

Purpose BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal
cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 …

Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT) status in metastatic colorectal cancer …

Purpose To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a
selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer …

PURPOSE To determine the safety and preliminary efficacy of selective combination
targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety …

The MAPK cascade plays a crucial role in tumor cell proliferation and survival. Accumulating
evidence suggests that mutations in the BRAF oncogene are not only associated with poor …

Background Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose
underlying genetic lesion is still obscure. Methods We searched for HCL-associated …